Kaigen Of Japan Plans 10 Percent Increase In Sales Staff
This article was originally published in PharmAsia News
Executive Summary
Japan's Kaigen plans a 10 percent annual increase in its sales staff to cover more institutions for two of its primary medical products. The firm said an X-ray barium contrast agent and its Alloid G treatment for peptic ulcer and reflex account for a large percentage of its sales. Alloid G alone accounts for about 30 percent, Kaigen said, and it hopes to double those sales within the next three years. The firm said part of its failure to cover all institutions in the country was its new business selling sterilizing devices and other medical equipment. (Click here for more - a subscription may be required